← Russell 3000 cross-section

AZTA Azenta, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$614m
Net income TTM
$-123m
Free cash flow
$10m
Composite score
54.5
Sector rank
#1807

Valuation

P / E
EV / EBITDA
EV / sales
1.9
FCF yield
0.67%
Earnings yield vs 10-yr
-13.08pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-20.0%
EBITDA margin
ROE
-8.1%
ROIC
-14.8%
Revenue growth
4.8%

Insider activity, last 90 days

Net open-market
$0.01m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

This strategic action is intended to simplify our portfolio and allow management to focus on driving revenue growth and profitability in our core Sample Management Solutions, or SMS, and Multiomics segments. The revenue growth in our SMS segment for the three and nine months ended June 30, 2026 compared to the corresponding periods in the prior fiscal year was primarily driven by higher revenue in Sample Storage and Consumables and Instruments, as well as revenue contributions from the acquired UK Biocentre business , partially offset by lower revenues in Core Products, particularly in Automated Stores. …Azenta, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →